Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 211

Sort by

Sort Order Select

Journal Articles

Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A -Rearranged BCP-ALL

Blood (2024) 144 (Supplement 1): 318.

https://doi.org/10.1182/blood-2024-199017

Published: 2024

Journal Articles

Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia

Steffen Krohn, Carina Lynn Gehlert, Dorothee Winterberg, Alexander Jochimsen, Ammelie Svea Boje, Natalie Baum, Claudia D Baldus, Monika Brüggemann, Gunnar Cario, Martin Schrappe, Lennart Lenk, Martin Gramatzki, Katja Klausz, Christian Kellner, Matthias Peipp

Blood (2024) 144 (Supplement 1): 4173.

https://doi.org/10.1182/blood-2024-207737

Published: 2024

Journal Articles

Role of Stem-like Cells in Chemotherapy Resistance and Relapse in Pediatric T Cell Acute Lymphoblastic Leukemia (T-ALL)

Julia Costea, Kerstin K. Rauwolf, Pietro Zafferani, Tobias Rausch, Anna Mathioudaki, Judith Zaugg, Martin Schrappe, Cornelia Eckert, Gabriele Escherich, Jean-Pierre Bourquin, Beat Bornhauser, Andreas E. Kulozik, Jan O. Korbel

Blood (2024) 144 (Supplement 1): 314.

https://doi.org/10.1182/blood-2024-199619

Published: 2024

Journal Articles

A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009

Blood (2024) 144 (Supplement 1): 309.

https://doi.org/10.1182/blood-2024-204943

Published: 2024

Journal Articles

CD127-Directed Immunotherapy with Lusvertikimab Outperforms Imatinib in Preclinical ABL-Class-Fusion-Positive BCP-ALL

Blood (2024) 144 (Supplement 1): 636.

https://doi.org/10.1182/blood-2024-205421

Published: 2024

Journal Articles

Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

Blood (2024) 144 (Supplement 1): 730.

https://doi.org/10.1182/blood-2024-201936

Published: 2024

Journal Articles

The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis

Blood (2024) 143 (26): 2735–2748.

https://doi.org/10.1182/blood.2023021088

Published: 2024

Includes: Supplemental data

Journal Articles

CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment

Blood (2024) 143 (17): 1738–1751.

https://doi.org/10.1182/blood.2023021952

Published: 2024

Includes: Supplemental data

Journal Articles

CNS Invasion of TCF3::PBX1 + Leukemia Cells Requires Upregulation of AP-1 Signaling As Revealed By Brain Organoid Model

Philip Gebing, Stefanos Loizou, Sebastian Hänsch, Julian Schliehe-Diecks, Lea Spory, Pawel Stachura, Aleksandra Pandyra, Martin Schrappe, Gunnar Cario, Ameera Alsadeq, Denis Martin Schewe, Arndt Borkhardt, Lennart Lenk, Ute Fischer, Sanil Bhatia

Blood (2023) 142 (Supplement 1): 1407.

https://doi.org/10.1182/blood-2023-178613

Published: 2023

Journal Articles

STAG2/LMO2 Gamma-Delta (γδ) T-ALL: Identification and Characterization of an Extremely High Risk Group of T-ALL in the Very Young

Shunsuke Kimura, Petri Pölönen, Lindsey Montefiori, Kenneth Caldwell, Ilaria Iacobucci, Chelsey Chen, Anthony Brown, Katie Han, Yen-Chun Liu, Yunchao Chang, Zhongshan Cheng, Zhou Yinmei, Chun Shik Park, Sharnise Mitchell, Noemi Reyes, Allen Yeoh, Andishe Attarbaschi, Andrew Moore, Atsushi Manabe, Barbara Buldini, Kean Hui Chiew, Chi Kong Li, Ching-Hon Pui, Chunxu Qu, Daisuke Tomizawa, Elisabeth Paietta, Franco Locatelli, Gabriele Escherich, Gao Qingsong, Hannah Elisa Muhle, Hanne Vibeke Marquart, Hester A. de Groot-Kruseman, Jacob M. Rowe, Jan Stary, Jan Trka, John Kim Choi, Jules P.P. Meijerink, Junko Takita, Katarzyna Pawinska-Wasikowska, Kjeld Schmiegelow, Mariko Eguchi, Martin Schrappe, Martin Zimmermann, Masatoshi Takagi, Melissa Maybury, Michael Svaton, Michaela Reiterova, Michal Kicinski, Motohiro Kato, Orietta Spinelli, Pauline Mazilier, Paul G. Thomas, Riccardo Masetti, Rishi Sury Kotecha, Rob Pieters, Sarah Elitzur, Selina M Luger, Shuhong Shen, Sima Jeha, Steven M. Kornblau, Szymon Skoczen, Takako Miyamura, Tiffaney Vincent, Toshihiko Imamura, Valentino Conter, Yanjing Tang, Zhaohui Gu, Kathryn G. Roberts, David T. Teachey, Kristine R Crews, Cheng Cheng, Jun J. Yang, Hiroto Inaba, Charles G. Mullighan

Blood (2023) 142 (Supplement 1): 845.

https://doi.org/10.1182/blood-2023-178688

Published: 2023

Journal Articles

Drug Response Profiling Informs Personalized Bridging to Cell Therapy for Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 4350.

https://doi.org/10.1182/blood-2023-179306

Published: 2023

Journal Articles

Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017

Blood (2023) 142 (Supplement 1): 825.

https://doi.org/10.1182/blood-2023-181524

Published: 2023

Journal Articles

In-Depth Immune Profiling in Children with BCP-ALL within the AIEOP-BFM ALL 2017 Study

Blood (2023) 142 (Supplement 1): 595.

https://doi.org/10.1182/blood-2023-186998

Published: 2023

Journal Articles

A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 As a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 4190.

https://doi.org/10.1182/blood-2023-185875

Published: 2023

Journal Articles

Recurrent DNMT3B Alterations Are Associated with Unfavorable Outcome in Dicentric (9;20)-Positive Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Željko Antić, Alena van Bömmel, Konstantin Riege, Jana Lentes, Charlotte Schröder, Julia Alten, Lara Fuhrmann, Martin Zimmermann, Cornelia Eckert, Gunnar Cario, Martin Schrappe, Brigitte Schlegelberger, Steve Hoffmann, Anke K. Bergmann

Blood (2022) 140 (Supplement 1): 9185–9186.

https://doi.org/10.1182/blood-2022-163404

Published: 2022

Journal Articles

Ph-like and IKZF1plus Features in Children with Down Syndrome and B Cell Precursor Acute Lymphoblastic Leukemia

Blood (2022) 140 (Supplement 1): 6367–6368.

https://doi.org/10.1182/blood-2022-169131

Published: 2022

Journal Articles

BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Different Clinical Behavior and Relevance of Prognostic Features in Typical ALL and in CML-like Disease

Blood (2022) 140 (Supplement 1): 9179–9180.

https://doi.org/10.1182/blood-2022-158926

Published: 2022

Journal Articles

Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol

Blood (2022) 140 (Supplement 1): 109–111.

https://doi.org/10.1182/blood-2022-166583

Published: 2022

Journal Articles

A Multi-Cohort Gene Expression Classifier (ALLCatchR) Identifies B-Precursor ALL Subtypes and Their Developmental Trajectories across Age Groups

Blood (2022) 140 (Supplement 1): 1053–1055.

https://doi.org/10.1182/blood-2022-163311

Published: 2022

Journal Articles

Hypersensitivity Reactions to Native E. coli L-Asparaginase in Children with Acute Lymphoblastic Leukemia May Vary By Treatment Schedule and Type of Glucocorticoid in Induction: Results of Trial ALL-BFM 2000

Blood (2022) 140 (Supplement 1): 11676–11678.

https://doi.org/10.1182/blood-2022-163142

Published: 2022

NARROW

Drug Sensitivity and Treatment Response Are Modulated By the Cell of Origin, the Underlying Gene Fusion, and Patient Age in KMT2A -Rearranged BCP-ALL

Preclinical Development of a Novel Humanized and Fc-Engineered Antibody-Drug Conjugate for the Therapy of T-Cell Acute Lymphoblastic Leukemia

Role of Stem-like Cells in Chemotherapy Resistance and Relapse in Pediatric T Cell Acute Lymphoblastic Leukemia (T-ALL)

A Reduced Daunorubicin Dose during Induction Is Equally Effective As Standard Dose in Children with Acute Lymphoblastic Leukemia (ALL) and Favorable Prognostic Features: Long-Term Results of the Phase 3 Trial AIEOP-BFM ALL 2009

CD127-Directed Immunotherapy with Lusvertikimab Outperforms Imatinib in Preclinical ABL-Class-Fusion-Positive BCP-ALL

Results in Pediatric T-ALL Patients Treated in Trial AIEOP-BFM ALL 2009: Exploring Prognostic Factors in the Context of Modern Risk Adapted Therapy

The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis

CD371-positive pediatric B-cell acute lymphoblastic leukemia: propensity to lineage switch and slow early response to treatment

CNS Invasion of TCF3::PBX1 + Leukemia Cells Requires Upregulation of AP-1 Signaling As Revealed By Brain Organoid Model

STAG2/LMO2 Gamma-Delta (γδ) T-ALL: Identification and Characterization of an Extremely High Risk Group of T-ALL in the Very Young

Drug Response Profiling Informs Personalized Bridging to Cell Therapy for Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017

In-Depth Immune Profiling in Children with BCP-ALL within the AIEOP-BFM ALL 2017 Study

A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 As a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia

Recurrent DNMT3B Alterations Are Associated with Unfavorable Outcome in Dicentric (9;20)-Positive Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

Ph-like and IKZF1plus Features in Children with Down Syndrome and B Cell Precursor Acute Lymphoblastic Leukemia

BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Different Clinical Behavior and Relevance of Prognostic Features in Typical ALL and in CML-like Disease

Impact of Additional Intensive L-Asparaginase Therapy during Consolidation Phase for High-Risk Acute Lymphoblastic Leukemia: Results of a Randomized Controlled Trial in the AIEOP-BFM ALL 2009 Protocol

A Multi-Cohort Gene Expression Classifier (ALLCatchR) Identifies B-Precursor ALL Subtypes and Their Developmental Trajectories across Age Groups

Hypersensitivity Reactions to Native E. coli L-Asparaginase in Children with Acute Lymphoblastic Leukemia May Vary By Treatment Schedule and Type of Glucocorticoid in Induction: Results of Trial ALL-BFM 2000

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only